

ASX RELEASE

31st October 2023

QUARTERLY ACTIVITIES AND CASH FLOW REPORTS

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), a company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce further progress across its small molecule, focal adhesion kinase (FAK) inhibitor program and the release of its Appendix 4C Cash Flow Report (attached) for the quarter ending 30 September 2023.

Key Highlights from the Quarter

- The third patient cohort in the Phase 1b stage of the ACCENT trial was expanded and dosing has continued.
- A new batch of narmafotinib capsules was manufactured.
- A poster presentation extensively describing preclinical data of narmafotinib (AMP945) in models of pancreatic cancer was presented at a prestigious international meeting.

Operations Update

Clinical Development

The primary focus of the company continues to be the ACCENT clinical trial in advanced pancreatic cancer patients. This trial tests the activity of our FAK inhibitor narmafotinib in combination with the standard-of-care chemotherapy regime of gemcitabine combined with nab-paclitaxel (Abraxane®). The trial consists of two phases: the Phase 1b stage where a safe and well-tolerated dose of narmafotinib is identified; and, the Phase 2a stage where efficacy of the drug (at the determined dose from Phase 1b) is determined in a larger patient group. This quarter, a dose-limiting toxicity (DLT) was observed in one patient in Cohort 3, and consistent with our clinical trial protocol, a further 3 patients at this dose have been recruited. The assessment of safety and tolerability of this dose in the expanded cohort has continued through September.

We anticipate moving to the Phase 2a dose escalation stage of the trial shortly and planning is well advanced to bring on additional sites in South Korea by the end of the year.

The production of an additional batch of capsules of narmafotinib to support our ongoing ACCENT clinical trial was completed this quarter. This work was conducted at our US-based Contract Drug Manufacturing Organisation under Good Manufacturing Practice following the validated processes already established. The capsule production run, and subsequent bottling and labelling, was completed on time and on-budget with no issues identified.

Non-clinical Development

A poster presentation describing extensive preclinical research demonstrating that narmafotinib modulates the fibrotic tumour microenvironment and prolongs survival in multiple models of pancreatic cancer in the mouse was presented at the prestigious *American Association of Cancer Research – Pancreatic Cancer* meeting in Boston. This meeting is attended by key opinion leaders in pancreatic cancer, along with leading scientists and clinicians from academia and industry, allowing us to gain valuable publicity of our work and progress.

Financial update

Amplia finished the September 2023 quarter with cash of \$5.7 million (June 2023: \$7.8 million).

During the quarter, the Company had net cash outflows of \$2.2 million in relation to operating activities (June 2023: \$1.4 million). Operating cashflows included outflows and inflows of:

- \$0.6 million for staff and administration/corporate costs; and
- \$1.5 million for research and development costs, which primarily related to trial costs, Contract Research Organisation (CRO), manufacturing and other Chemistry, Manufacturing and Controls (CMC) related costs incurred in relation to the first stage of the Phase 1b/2a clinical trial of narmafotinib.

Research and development expenditure is forecast to increase in the coming quarters in line with the progression of Phase 1b/2a of the ACCENT clinical trial of narmafotinib.

The Company is expecting to receive the FY23 Research and Development Tax Incentive refund of \$2,408,458 in October 2023 with which it will then repay the \$2,100,000 Research and Development Tax Incentive loan that it holds with Treasury Corporation of Victoria that was drawn down as part of the Victorian Government's R&D Cash Flow Loan Initiative.

Payments to Related Entities

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors' fees, salaries and superannuation. Total payments made for the quarter equals \$175,308 and relate to payments to the CEO/Managing Director in line with employment contracts and payments to the Non-Executive Directors.

Outlook and future activities

Over the coming quarter, the Company expects to complete the dose escalation (Phase 1b) stage of the ACCENT trial and initiate the Phase 2 portion of the trial. We also plan to open five trial sites in Korea by the end of this calendar year.

Preliminary data from preclinical studies with narmafotinib in ovarian cancer models will be presented at an international conference in October. The potential of FAK inhibitors in ovarian cancer is gaining increasing attention after exciting clinical data for the first generation FAK inhibitor defactinib was reported by US biotech Verastem at this year's *American Society of Clinical Oncology* annual meeting.

- End -

For Further Information

Dr. Christopher Burns
CEO and Managing Director
Chris@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in cancer and Amplia has a particular development focus in fibrotic tumours such as pancreatic and ovarian cancers. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AMPLIA THERAPEUTICS LIMITED

ABN

16 165 160 841

Quarter ended ("current quarter")

30 September 2023

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(1,496)	(2,137)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(354)	(832)
(f) administration and corporate costs	(294)	(587)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	48	77
1.5 Interest and other costs of finance paid	(23)	(45)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	(56)	(64)
1.9 Net cash from / (used in) operating activities	(2,175)	(3,588)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-
3. Cash flows from financing activities			
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (repayment of lease liability)	(20)	(40)
3.10	Net cash from / (used in) financing activities	(20)	(40)
4. Net increase / (decrease) in cash and cash equivalents for the period			
4.1	Cash and cash equivalents at beginning of period	7,829	9,257
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,175)	(3,588)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(20)	(40)
4.5	Effect of movement in exchange rates on cash held	23	28
4.6	Cash and cash equivalents at end of period	5,657	5,657

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	485	962
5.2	Call deposits	5,172	6,867
5.3	Bank overdrafts	-	-
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,657	7,829

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	175
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

The amount at 6.1 includes Director fees and salary (including superannuation) for the CEO and Managing Director and Non-Executive Directors.

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	2,100	2,100
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	2,100	2,100
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	<p>The Loan facility is a non-dilutive funding facility of up to \$2.1million with Treasury Corporation of Victoria (TCV) as part of the Victorian Government's R&D Cash Flow Loan Initiative. The Facility was received in two tranches: the first of \$1.26 million was received in December 2021; and the second of \$0.84 million was received in February 2022. The amount of the second tranche funding was capped so as not to exceed a total Facility draw down of 80% of the Company's forecast R&D Tax Incentive (RDTI) rebate for FY2022. Interest on Facility advances is variable at the "TCV 11am" loan interest rate (currently 4.265%). Repayment of the Facility is timed to coincide with receipt of the Company's FY2023 RDTI refund, expected by 31 October 2023, but may be repaid earlier. The Facility is secured by the FY2022 and FY2023 RDTI refunds. As at 30 September 2023, the total loan facility was \$2.10 million, being fully drawn.</p>	

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(2,175)
8.2 Cash and cash equivalents at quarter end (item 4.6)	5,657
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	5,657
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.6
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 October 2023

Authorised by: The Board of Amplia Therapeutics Limited
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.